MANSI PATEL: Open Payments
NPI 1720677925 · WAUKESHA, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$334 in 13 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $234 · 2025 $334
Food & beverage: $334
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 1 | $107 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Lilly USA, LLC | 2 | $31 |
| Lundbeck LLC | 1 | $23 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $23 |
| Neurocrine BioSciences, Inc. | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| ABBVIE INC. | 1 | $20 |
| PFIZER INC. | 1 | $15 |
| SANOFI-AVENTIS U.S. LLC | 1 | $14 |
Products named: Epclusa, REXULTI, MOUNJARO, Kerendia, INGREZZA, VOWST, VRAYLAR, PREVNAR 20.
Industry payments across WI — which companies pay providers there.
